Skip to main content

Advertisement

Fig. 1 | BMC Cancer

Fig. 1

From: 18F-fluoride positron emission tomography/computed tomography and bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancer patients: study protocol for a multicentre, diagnostic test accuracy study

Fig. 1

Schematic drawing of the treatment response of planar bone scintigraphy and 18F-fluoride PET/CT. a Baseline imaging with planar bone scintigraphy (BS); BS shows two lesions in the pelvic region, one lesion in a vertebra, and lesions at both hip joint surfaces. b 18F-fluoride PET/CT demonstrate two additional lesions that were not detected by BS (marked with blue circle). c Post-ADT imaging with BS. d Post-ADT imaging with 18F-fluoride PET/CT. All lesions detected by BS, which are not located near joints, showed partial (n = 2) or complete (n = 1) regression and thus were defined as bone metastases. All the lesions detected by 18F-fluoride PET/CT, which are not located near joints, regressed (n = 5). Thus, 18F-fluoride PET/CT detected two lesions that were not detected by BS, these are defined as true positive on18F-fluoride PET/CT and consequently as false negative on BS. ADT androgen deprivation therapy. The illustration is copyright of Nuclear Medicine Aalborg

Back to article page